Literature DB >> 27187609

Toward the Validation of Maternal Embryonic Leucine Zipper Kinase: Discovery, Optimization of Highly Potent and Selective Inhibitors, and Preliminary Biology Insight.

B Barry Touré1, John Giraldes1, Troy Smith1, Elizabeth R Sprague1, Yaping Wang1, Simon Mathieu1, Zhuoliang Chen1, Yuji Mishina1, Yun Feng1, Yan Yan-Neale1, Subarna Shakya1, Dongshu Chen1, Matthew Meyer1, David Puleo1, J Tres Brazell1, Christopher Straub1, David Sage1, Kirk Wright1, Yanqiu Yuan1, Xin Chen1, Jose Duca1, Sean Kim1, Li Tian1, Eric Martin1, Kristen Hurov1, Wenlin Shao1.   

Abstract

MELK kinase has been implicated in playing an important role in tumorigenesis. Our previous studies suggested that MELK is involved in the regulation of cell cycle and its genetic depletion leads to growth inhibition in a subset of high MELK-expressing basal-like breast cancer cell lines. Herein we describe the discovery and optimization of novel MELK inhibitors 8a and 8b that recapitulate the cellular effects observed by short hairpin ribonucleic acid (shRNA)-mediated MELK knockdown in cellular models. We also discovered a novel fluorine-induced hydrophobic collapse that locked the ligand in its bioactive conformation and led to a 20-fold gain in potency. These novel pharmacological inhibitors achieved high exposure in vivo and were well tolerated, which may allow further in vivo evaluation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27187609     DOI: 10.1021/acs.jmedchem.6b00052

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

Review 1.  Enigmatic MELK: The controversy surrounding its complex role in cancer.

Authors:  Ian M McDonald; Lee M Graves
Journal:  J Biol Chem       Date:  2020-04-29       Impact factor: 5.157

2.  Arrestin-3 interaction with maternal embryonic leucine-zipper kinase.

Authors:  Nicole A Perry; Kevin P Fialkowski; Tamer S Kaoud; Ali I Kaya; Andrew L Chen; Juliana M Taliaferro; Vsevolod V Gurevich; Kevin N Dalby; T M Iverson
Journal:  Cell Signal       Date:  2019-07-25       Impact factor: 4.315

3.  Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1.

Authors:  Lakshmi Reddy Bollu; Jonathan Shepherd; Dekuang Zhao; Yanxia Ma; William Tahaney; Corey Speers; Abhijit Mazumdar; Gordon B Mills; Powel H Brown
Journal:  NPJ Breast Cancer       Date:  2020-01-03

4.  MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway.

Authors:  Radoslav Janostiak; Navin Rauniyar; TuKiet T Lam; Jianhong Ou; Lihua J Zhu; Michael R Green; Narendra Wajapeyee
Journal:  Cell Rep       Date:  2017-12-05       Impact factor: 9.423

5.  CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy.

Authors:  Rachel L Mintz; Madeleine A Gao; Kahmun Lo; Yeh-Hsing Lao; Mingqiang Li; Kam W Leong
Journal:  Adv Biosyst       Date:  2018-08-17

Review 6.  Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.

Authors:  George M Burslem; Craig M Crews
Journal:  Cell       Date:  2020-01-16       Impact factor: 41.582

7.  Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells.

Authors:  Ian M McDonald; Gavin D Grant; Michael P East; Thomas S K Gilbert; Emily M Wilkerson; Dennis Goldfarb; Joshua Beri; Laura E Herring; Cyrus Vaziri; Jeanette Gowen Cook; Michael J Emanuele; Lee M Graves
Journal:  J Biol Chem       Date:  2020-01-02       Impact factor: 5.157

8.  Consensus Virtual Screening Identified [1,2,4]Triazolo[1,5-b]isoquinolines As MELK Inhibitor Chemotypes.

Authors:  Anita Rácz; Roberta Palkó; Dorottya Csányi; Zsuzsanna Riedl; Dávid Bajusz; György M Keserű
Journal:  ChemMedChem       Date:  2021-10-19       Impact factor: 3.540

9.  The target landscape of clinical kinase drugs.

Authors:  Susan Klaeger; Stephanie Heinzlmeir; Mathias Wilhelm; Harald Polzer; Binje Vick; Paul-Albert Koenig; Maria Reinecke; Benjamin Ruprecht; Svenja Petzoldt; Chen Meng; Jana Zecha; Katrin Reiter; Huichao Qiao; Dominic Helm; Heiner Koch; Melanie Schoof; Giulia Canevari; Elena Casale; Stefania Re Depaolini; Annette Feuchtinger; Zhixiang Wu; Tobias Schmidt; Lars Rueckert; Wilhelm Becker; Jan Huenges; Anne-Kathrin Garz; Bjoern-Oliver Gohlke; Daniel Paul Zolg; Gian Kayser; Tonu Vooder; Robert Preissner; Hannes Hahne; Neeme Tõnisson; Karl Kramer; Katharina Götze; Florian Bassermann; Judith Schlegl; Hans-Christian Ehrlich; Stephan Aiche; Axel Walch; Philipp A Greif; Sabine Schneider; Eduard Rudolf Felder; Juergen Ruland; Guillaume Médard; Irmela Jeremias; Karsten Spiekermann; Bernhard Kuster
Journal:  Science       Date:  2017-12-01       Impact factor: 47.728

10.  An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor.

Authors:  Daniel Zaidman; Paul Gehrtz; Mihajlo Filep; Daren Fearon; Ronen Gabizon; Alice Douangamath; Jaime Prilusky; Shirly Duberstein; Galit Cohen; C David Owen; Efrat Resnick; Claire Strain-Damerell; Petra Lukacik; Haim Barr; Martin A Walsh; Frank von Delft; Nir London
Journal:  Cell Chem Biol       Date:  2021-06-25       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.